Search Results
Jan 27, 2026, 17:31 ET Pharma Conference Coverage Services: Real-Time Pharma Intelligence to Power Strategic Decision-Making
https://www.delveinsight.com/consulting/conference-coverage-services?utm_source=cision&utm_medium=pressrelease&utm_campaign=sprWhat DelveInsight's Conference Coverage Delivers?Pre-Conference
More news about: DelveInsight Business Research, LLP
Jan 26, 2026, 17:31 ET RET Fusion Targeted Therapies Market Set for Robust Growth by 2034 Amid Precision Oncology Shift | DelveInsight
https://www.delveinsight.com/report-store/ret-fusion-market-forecast?utm_source=cision&utm_medium=pressrelease&utm_campaign=sprKey Factors Driving the RET Fusion Targeted Therapies Market
More news about: DelveInsight Business Research, LLP
Jan 22, 2026, 17:31 ET Gastroesophageal Reflux Disease Market in the US to Show Promising Growth at a CAGR of 6% During the Forecast Period (2025-2034) | DelveInsight
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=sprKey Factors Driving the Growth of the Gastroesophageal Reflux
More news about: DelveInsight Business Research, LLP
Jan 21, 2026, 17:31 ET Cystinosis Market to Grow at a Substantial Growth Rate of 5.1% During the Forecast Period (2025-2034) | DelveInsight
https://www.delveinsight.com/sample-request/cystinosis-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=sprKey Factors Driving the Growth of the Cystinosis Market Increased
More news about: DelveInsight Business Research, LLP
Jan 20, 2026, 17:31 ET PSMA-Targeted Therapy Market Set to Expand by 2034 on Strong Pipeline and Increasing Diagnosis Rates | DelveInsight
https://www.delveinsight.com/sample-request/psma-targeted-therapy-market-forecast?utm_source=cision&utm_medium=pressrelease&utm_campaign=sprKey Factors Driving the PSMA-targeted Therapy Market
More news about: DelveInsight Business Research, LLP
Jan 19, 2026, 17:31 ET Underactive Bladder Syndrome Market to Observe Stunning Growth at a CAGR of 22.1% During the Forecast Period (2025-2034) | DelveInsight
https://www.delveinsight.com/sample-request/underactive-bladder-syndrome-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=sprKey Factors Driving the Growth of the Underactive Bladder Syndrome
More news about: DelveInsight Business Research, LLP
Jan 18, 2026, 19:02 ET Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
BioMed, in connection with a license and collaboration agreement by and between HBMAT and Spruce. The collaboration aims to advance the development of SPR202 (formerly known as HBM9013 by Harbour BioMed), a potent and selective anti-corticotropin-releasing hormone monoclonal antibody for various disorders,
More news about: Harbour BioMed
Jan 15, 2026, 17:31 ET Hemophagocytic Lymphohistiocytosis Market Poised for Phenomenal Expansion in the US at a CAGR of 24.5% During the Forecast Period (2025-2034) | DelveInsight
https://www.delveinsight.com/sample-request/hemophagocytic-lymphohistiocytosis-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=sprKey Factors Driving the Growth of the Hemophagocytic Lymphohistiocytosis
More news about: DelveInsight Business Research, LLP
Jan 14, 2026, 17:31 ET House Dust Mite Disease Market to Exhibit Substantial Growth at a CAGR of 3.5% During the Forecast Period (2025-2034) | DelveInsight
https://www.delveinsight.com/sample-request/house-dust-mite-disease-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=sprKey Factors Driving the Growth of the House Dust Mite Disease Market
More news about: DelveInsight Business Research, LLP
Dec 15, 2025, 01:28 ET Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.
integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, DEL, ASMS, SPR, HDX, AIDD/CADD, and much more. Our business covers all aspects of therapeutic strategies and drug modalities, including small molecules and biologics
More news about: Viva Biotech
Dec 15, 2025, 01:06 ET Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.
integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, DEL, ASMS, SPR, HDX, AIDD/CADD, and much more. Our business covers all aspects of therapeutic strategies and drug modalities, including small molecules and biologics
More news about: Viva Biotech
Dec 08, 2025, 08:40 ET Boeing Completes Acquisition of Spirit AeroSystems
Dec. 8, 2025 /PRNewswire/ -- Boeing [NYSE: BA] today announced it has completed its acquisition of Spirit AeroSystems [NYSE: SPR].
More news about: Boeing
Dec 04, 2025, 11:01 ET Pediatric Academic Societies 2026 Meeting in Boston: Bringing the Global Pediatric Community Together to Shape the Future of Child Health
Society for Pediatric Research (SPR).For more information, visit
More news about: Pediatric Academic Societies Meeting
Nov 24, 2025, 09:00 ET Kinetic Technologies Announces Transient Voltage Suppression (TVS) Flat-Clamp Integrated Circuits for Port Protection Against High Voltage Surge and ESD Events
KTS1287: Up to ±250V Surge Protection for 20V SPR VBUS Components, KTS1289: Up to ±200V Surge Protection for 28V EPR VBUS Components, both Providing Top-Notch ESD Protection Performance at +30kV Contact & Air-Gap All in a Tiny WLCSP 1.66 x 1.56mm Package
More news about: Kinetic Technologies
Oct 31, 2025, 16:15 ET Spirit AeroSystems Reports Third Quarter 2025 Results
operations of $187 million; Free cash flow* usage of $230 million Spirit AeroSystems Holdings, Inc. (NYSE: SPR) ("Spirit," "Spirit AeroSystems" or the "Company") reported third quarter 2025 financial results. Revenue
More news about: Spirit AeroSystems Holdings, Inc.
Oct 27, 2025, 09:01 ET Beazley Security Targets Risk Reduction Through Broad Availability of Security Posture Reports
The tooling that powers the SPR was designed in 2022 to provide a rapid assessment of cyber risk during the application and renewal processes for cyber insurance. Beazley Security has
More news about: Beazley Security
Oct 15, 2025, 08:47 ET Uncle Matt's Organic® Launches First-Ever Organic Yerba Mate Energy Tea
shop.unclematts.com, as well as nationwide at Whole Foods Market and Sprouts Farmers Market beginning October 2025 with an SPR of $4.99. With its refreshing flavor and functional benefits, this tea is the perfect pick-me-up for any time of day.
More news about: Uncle Matt's Organic
Sep 29, 2025, 05:01 ET Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry
integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, DEL, ASMS, SPR, HDX, AIDD/CADD, and much more. Our business covers all aspects of therapeutic strategies and drug modalities, including small molecules and biologics
More news about: Viva Biotech
Sep 29, 2025, 05:00 ET Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry
integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, DEL, ASMS, SPR, HDX, AIDD/CADD, and much more. Our business covers all aspects of therapeutic strategies and drug modalities, including small molecules and biologics
More news about: Viva Biotech
Sep 29, 2025, 00:00 ET Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry
integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, DEL, ASMS, SPR, HDX, AIDD/CADD, and much more. Our business covers all aspects of therapeutic strategies and drug modalities, including small molecules and biologics
More news about: Frost & Sullivan
Sep 29, 2025, 00:00 ET Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry
integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, DEL, ASMS, SPR, HDX, AIDD/CADD, and much more. Our business covers all aspects of therapeutic strategies and drug modalities, including small molecules and biologics
More news about: Frost & Sullivan
Sep 24, 2025, 16:00 ET Synopsys Collaborates with TSMC to Drive the Next Wave of AI and Multi-Die Innovation
performance, power, and to scale chip designs to advanced semiconductor technologies. Certified capabilities for designs on TSMC A16™ Super Power Rail (SPR) process improve power distribution and system performance, while maintaining thermal robustness of backside routing designs. Synopsys' pattern-based
More news about: Synopsys, Inc.